Substance
ID:167
Names and Identifiers
Synonyms
Acide pamidronique [INN-French]Acido pamidronico [INN-Spanish]Acidum pamidronicum [INN-Latin]APDPamidronatePamidronate DisodiumPamidronic acid
Brand Name
AminomuxAmidronateAredia
IUPAC name
(3-amino-1-hydroxy-1-phosphonopropyl)phosphonic acid
IUPAC Traditional name
pamidronate
Properties
Physical Property
Hydrophobicity(logP)
-4.7
Molecule Details
Drug Groups
approved
Description
Pamidronic acid (INN) or pamidronate disodium (USAN), marketed as pamidronate disodium pentahydrate under the brand name Aredia, is a bisphosphonate. [Wikipedia]
Indication
For the treatment of moderate or severe hypercalcemia associated with malignancy
Pharmacology
Pamidronate is in a class of drugs called bisphosphonates. Pamidronate reduces breakdown of the bones. Pamidronate is used in the treatment of Paget's disease of bone; to reduce high levels of calcium in the blood associated with malignancy (cancer); and to reduce the breakdown of bone due to metastases of breast cancer or multiple myeloma.
Toxicity
Side effects include an allergic reaction, kidney problems, seizures, low levels of calcium, magnesium, or phosphorus in the blood
Affected Organisms
Humans and other mammals
Biotransformation
Pamidronate is not metabolized and is exclusively eliminated by renal excretion
Absorption
Plasma concentration rises rapidly upon IV administration.
Half Life
The mean ± SD elimination half-life is 28 ± 7 hours
Protein Binding
Approximately 54% to human serum proteins.
Elimination
Pamidronate is not metabolized and is exclusively eliminated by renal excretion.
Clearance
* 107 +/- 50 mlL/min
References
•
Zarychanski R, Elphee E, Walton P, Johnston J: Osteonecrosis of the jaw associated with pamidronate therapy. Am J Hematol. 2006 Jan;81(1):73-5.
[Pubmed]
External Links
Molecular Spectra
No Data Available
Click here to submit data
References
• Zarychanski R, Elphee E, Walton P, Johnston J: Osteonecrosis of the jaw associated with pamidronate therapy. Am J Hematol. 2006 Jan;81(1):73-5. Pubmed